Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer (Q38214154)

31 August 2017

Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer (English)

1 reference

31 August 2017

1 reference

1 reference

Johan F Vansteenkiste

series ordinal

1

1 reference

PubMed ID

24856155

31 August 2017

language of work or name

English

0 references

publication date

23 May 2014

1 reference

31 August 2017

1 reference

31 August 2017

10

1 reference

31 August 2017

12

1 reference

31 August 2017

1925-1939

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

31 August 2017

1 reference

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials

21 January 2018

1 reference

Targeted therapy for NSCLC with driver mutations

21 January 2018

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

21 January 2018

1 reference

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers

21 January 2018

1 reference

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

21 January 2018

1 reference

Anaplastic lymphoma kinase in human cancer

21 January 2018

1 reference

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

21 January 2018

1 reference

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.

21 January 2018

1 reference

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases.

21 January 2018

1 reference

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

21 January 2018

1 reference

Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.

21 January 2018

1 reference

Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer

21 January 2018

1 reference

Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer

21 January 2018

1 reference

A mouse model for EML4-ALK-positive lung cancer

21 January 2018

1 reference

Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer

21 January 2018

1 reference

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry

21 January 2018

1 reference

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

21 January 2018

1 reference

Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?

21 January 2018

1 reference

The potential for crizotinib in non-small cell lung cancer: a perspective review

21 January 2018

1 reference

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

ALK in lung cancer: past, present, and future

21 January 2018

1 reference

Ceritinib in ALK-rearranged non-small-cell lung cancer

21 January 2018

1 reference

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

21 January 2018

1 reference

Berberine suppresses androgen receptor signaling in prostate cancer.

21 January 2018

1 reference

Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia

21 January 2018

1 reference

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

21 January 2018

1 reference

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

Sequencing technologies - the next generation

21 January 2018

1 reference

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer

21 January 2018

1 reference

The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models

21 January 2018

1 reference

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

21 January 2018

1 reference

The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth

21 January 2018

1 reference

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

21 January 2018

1 reference

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.14.94

1 reference

31 August 2017

1 reference

PubMed ID

24856155